In a collaborative study published in The Lancet Microbe, the team of scientists, led by the Peter Doherty Institute for Infection and Immunity (Doherty Institute) and WEHI (Walter and Eliza Hall Institute of Medical Research), revealed MPXV-CRISPR – a powerful diagnostic tool capable of detecting MPXV in clinical samples with acute precision and at a faster rate than any other method, thanks to the power of CRISPR technology.
Bayer set to expand Kerendia’s label in cardiology with Phase III win
Bayer’s Kerendia is approved by the FDA for reducing cardiovascular risks and kidney function decline in adult patients with chronic kidney disease associated with type
August 5, 2024